CervoMed (CRVO) Non Operating Income (2010 - 2026)
CervoMed (CRVO) posted Non Operating Income of $146366.0 for Q1 2026, down 40.07% sequentially from $244229.0 in Q4 2025, and down 64.2% YoY from $408850.0 in Q1 2025.
CervoMed (CRVO) Non Operating Income (2010 - 2026) Analysis & Trends
CervoMed has reported Non Operating Income for 17 years, with the latest figure at $146366.0 in Q1 2026.
- Quarterly Non Operating Income fell 64.2% year-over-year to $146366.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 52.93% YoY) and the FY2025 annual result came in at $1.3 million, down 31.39% from the prior year.
- Non Operating Income eased to $146366.0 in Q1 2026 per CRVO's latest filing, from $244229.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $4.8 million in Q3 2023 and troughed at -$588577.0 in Q4 2022.
- A 5-year average of $504022.1 and a median of $244229.0 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 6537.84% in 2022, then surged 22416.41% in 2023.
- Over 5 years, Non Operating Income stood at -$588577.0 in 2022, then surged by 120.06% to $118052.0 in 2023, then jumped by 353.11% to $534907.0 in 2024, then sank by 54.34% to $244229.0 in 2025, then slumped by 40.07% to $146366.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $146366.0, $244229.0, and $317560.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 106,895.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106,895.00 |
| Mar 31, 2026 | 146,366.00 |
| Dec 31, 2025 | 244,229.00 |
| Sep 30, 2025 | 317,560.00 |
| Jun 30, 2025 | 357,871.00 |
| Mar 31, 2025 | 408,850.00 |
| Dec 31, 2024 | 534,907.00 |
| Sep 30, 2024 | 642,732.00 |
| Jun 30, 2024 | 678,194.00 |
| Mar 31, 2024 | 80,603.00 |
| Dec 31, 2023 | 118,052.00 |
| Sep 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | -194,504.00 |
| Mar 31, 2023 | 891,983.00 |
| Dec 31, 2022 | -588,577.00 |
| Sep 30, 2022 | 21,431.00 |
| Jun 30, 2022 | 55,378.00 |
| Mar 31, 2022 | 27,809.00 |
| Dec 31, 2021 | -8,867.00 |
| Sep 30, 2021 | 50,710.00 |